InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).
Gladstone Institutes, a non-profit biomedical research organization that uses visionary science and technology to overcome disease, will leverage its expertise in immunology and virology to support the collaboration. Gladstone has made significant contributions to better understanding and developing new therapies for a range of viral diseases, including HIV/AIDS and COVID-19.
The collaboration aims to develop intranasal preventatives that can protect individuals from viral infections, including SARS-CoV-2, the virus that causes COVID-19, as well as influenza and RSV. Intranasal preventatives have the potential to serve as an immediate line of defense against viral infections, irrespective of an individual’s vaccination or immune system status, by targeting the nose and upper respiratory tract where most infections originate.